{"id":130009,"date":"2018-12-10T15:32:09","date_gmt":"2018-12-10T15:32:09","guid":{"rendered":"http:\/\/www.georgianewsdesk.com\/news\/story\/130009\/global-vitiligo-market-patients-by-countries-drugs-arn4079-ati502-ax1602-bos47-etc-companies-clinical-study-growth-drivers-challenges.html"},"modified":"2018-12-10T15:32:09","modified_gmt":"2018-12-10T15:32:09","slug":"global-vitiligo-market-patients-by-countries-drugs-arn4079-ati502-ax1602-bos47-etc-companies-clinical-study-growth-drivers-challenges","status":"publish","type":"post","link":"http:\/\/www.honolulunewsnow.com\/news\/story\/130009\/global-vitiligo-market-patients-by-countries-drugs-arn4079-ati502-ax1602-bos47-etc-companies-clinical-study-growth-drivers-challenges.html","title":{"rendered":"Global Vitiligo Market, Patients By Countries, Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, etc), Companies, Clinical Study, Growth Drivers, Challenges"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
Global Vitiligo market will be US$ 2.4 Billion by the year 2024. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of Vitiligo drugs are some of the driving force for the growth of this market.<\/div>\n<\/div>\n<\/div>\n
Renub Research report titled \u201cGlobal Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges\u201d provides a complete analysis of global vitiligo drugs market. <\/div>\n

Vitiligo is a long-term skin disease in which patches of the skin lose their color. The skin patches affected by the disease Vitiligo become white. This happens because melanocytes within the skin die off. The skin pigmentation, melanin, due to which skin has its color, protection from sun UV rays this all happens because of melanocytes cells. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of Vitiligo drugs are some of the driving force for the growth of this market. However, shortage of dermatologists and available treatments having longer duration of times are major challenges for the growth of this market. According to Renub Research global vitiligo market<\/a> will be US$ 2.4 Billion<\/strong> by the year 2024<\/strong>.<\/p>\n

Vitiligo disease prevalence varies between race, regions and countries. It is expected that overall prevalence fall between 1-2 percent<\/strong> of the total population. Although Vitiligo disease can arise at any age, it mostly occurs to young and middle age people. At present globally over 21 Million<\/strong> people has suffered from this diseases. There are number of drugs manufactures working for Vitiligo drugs development across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc. and their Vitiligo drugs development are in various stages.<\/p>\n

 <\/p>\n

Request a free sample copy of the report: https:\/\/www.renub.com\/contactus.php<\/a><\/p>\n

Renub Research<\/strong> report titled “Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges”<\/strong> provides a complete analysis of global vitiligo drugs market.<\/p>\n

India and China are Key Contributors in the Global Vitiligo Patient Population<\/strong><\/p>\n

Vitiligo patient’s population is growing across all parts of the world. Patient’s growth rates varies in the countries covered in the report United States, United Kingdom, France, Germany, Italy, India, China and Japan. India and China are key contributors in the global vitiligo patient population.<\/p>\n

Vitiligo Pipe Line Drugs are Key Strength for this Market Place<\/strong><\/p>\n

In the global vitiligo market, vitiligo pipe line drugs will play the major role for the growth of this market. At present several drugs such as ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001 etc. are in preclinical, IND, Phase I, Phase II and Phase III stage.<\/p>\n

 <\/p>\n

   \"\"<\/p>\n

 <\/p>\n

Key Drugs Development Companies are working in this Market Place<\/strong><\/p>\n

Key drugs development companies are working in this market place across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc.<\/p>\n

Segments – Global Vitiligo Market<\/strong><\/p>\n

• Vitiligo Patients Population
• Vitiligo Market<\/p>\n

Countries – Global Vitiligo Market<\/strong><\/p>\n

• United States
• United Kingdom
• France
• Germany
• Italy
• India
• China
• Japan<\/p>\n

 <\/p>\n

Client can Purchase this Report in Sections<\/strong> from below link:<\/p>\n

Access full Research: <\/strong>  https:\/\/www.renub.com\/global-vitiligo-market-p.php<\/a><\/p>\n

Global Vitiligo Market – Drugs Profile Covered<\/strong><\/p>\n

• ARN-4079
• ATI-502
• AX-1602
• BOS-47
• CCP-070
• Cerdulatinib (RVT-502)
• HuABC-2
• Abatacept
• Topical Ruxolitinib
• VLRX-001<\/p>\n

Companies Covered<\/strong><\/p>\n

• AXIM Biotechnologies
• Incyte Corporation
• Bristol-Myers Squibb
• Clinuvel Pharmaceuticals<\/p>\n

Each Company Covered in this Report has Following Details<\/strong><\/p>\n

• Company Overview
• Company Initiatives
• Financial Insight<\/p>\n

 <\/p>\n

If the information you seek is not included in the current scope of the study kindly share your specific requirements with <\/span>our custom research<\/strong> team at info@renub.com<\/span><\/p>\n

 <\/p>\n

Browse Related Report :<\/strong><\/p>\n

Spinal Muscular Atrophy Market<\/a><\/p>\n

Diabetes Drug Market<\/a><\/p>\n

 <\/p>\n

Contact Us<\/strong><\/p>\n

Renub Research<\/strong><\/p>\n

Phone:<\/strong>+1-678-302-0700<\/p>\n

Email:<\/strong> info@renub.com<\/p>\n

 <\/p>\n

Key Topics Covered :<\/strong><\/p>\n

 <\/p>\n

1. Introduction<\/strong><\/p>\n

1.1 Market Definition<\/p>\n

2. Research Methodology<\/strong><\/p>\n

3. Executive Summary<\/strong><\/p>\n

4. Global Vitiligo Patient Numbers & Market<\/strong><\/p>\n

4.1 Vitiligo Patients Numbers
4.2 Vitiligo Market<\/p>\n

5. Share – Global Vitiligo Patient Numbers & Market<\/strong><\/p>\n

5.1 Vitiligo Patient Numbers Share
5.2 Vitiligo Market Share<\/p>\n

6. United States<\/strong><\/p>\n

6.1 Vitiligo Patient Numbers
6.2 Vitiligo Market<\/p>\n

7. United Kingdom<\/strong><\/p>\n

7.1 Vitiligo Patient Numbers
7.2 Vitiligo Market<\/p>\n

8. France<\/strong><\/p>\n

8.1 Vitiligo Patient Numbers
8.2 Vitiligo Market<\/p>\n

9. Germany<\/strong><\/p>\n

9.1 Vitiligo Patient Numbers
9.2 Vitiligo Market<\/p>\n

10. Italy<\/strong><\/p>\n

10.1 Vitiligo Patient Numbers
10.2 Vitiligo Market<\/p>\n

11. India<\/strong><\/p>\n

11.1 Vitiligo Patient Numbers
11.2 Vitiligo Market<\/p>\n

12. China<\/strong><\/p>\n

12.1 Vitiligo Patient Numbers
12.2 Vitiligo Market<\/p>\n

13. Japan<\/strong><\/p>\n

13.1 Vitiligo Patient Numbers
13.2 Vitiligo Market<\/p>\n

14. Vitiligo Pipe Line Drugs<\/strong><\/p>\n

14.1 ARN-4079
14.2 ATI-502
14.3 AX-1602
14.4 BOS-475
14.5 CCP-070
14.6 Cerdulatinib (RVT-502)
14.7 HuABC-2
14.8 Abatacept
14.9 Topical Ruxolitinib
14.10 VLRX-001<\/p>\n

15. Clinical Study of Vitiligo Market<\/strong><\/p>\n

16. Growth Drivers<\/strong><\/p>\n

16.1 Growing Importance of Aesthetic Appeal
16.2 World Vitiligo Day: Increases Vitiligo Awareness<\/p>\n

17. Global Vitiligo Market – Challenges<\/strong><\/p>\n

17.1 Shortage of Dermatologists
17.2 Available Treatments are Not Much Effective<\/p>\n

18. AXIM Biotechnologies, Inc.<\/strong><\/p>\n

18.1 Company Overview
18.2 Initiatives
18.3 Financial Insight<\/p>\n

19. Incyte Corporation<\/strong><\/p>\n

19.1 Company Overview
19.2 Initiatives
19.3 Financial Insight<\/p>\n

20. Bristol-Myers Squibb<\/strong><\/p>\n

20.1 Company Overview
20.2 Initiatives
20.3 Financial Insight<\/p>\n

21. Clinuvel Pharmaceuticals Ltd<\/strong><\/p>\n

21.1 Company Overview
21.2 Company Initiatives
21.3 Financial Insight<\/p>\n

 <\/p>\n

About Us<\/strong><\/p>\n

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Renub Research<\/a>
Contact Person:<\/strong> Rajat Gupta
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 6783020700
Address:<\/strong>225 Kristie Ln
City:<\/strong> Roswell
State:<\/strong> GA
Country:<\/strong> United States
Website:<\/strong> www.renub.com\/life-science-1-c.php<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Global Vitiligo market will be US$ 2.4 Billion by the year 2024. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"_links":{"self":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/posts\/130009"}],"collection":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/comments?post=130009"}],"version-history":[{"count":0,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/posts\/130009\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/media?parent=130009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/categories?post=130009"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.honolulunewsnow.com\/news\/wp-json\/wp\/v2\/tags?post=130009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}